Biblio
A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD. Transplant Cell Ther. 2024.
Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.
A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.